We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current SCCPF market cap is 521.01M. The company's latest EPS is CNY 1.7875 and P/E is 0.46.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 1.71B | 1.92B | 2.52B | 2.75B | 3.16B |
| Operating Income | 655.32M | 806.46M | 1.04B | 1.11B | 1.26B |
| Net Income | 614.6M | 753.7M | 923.36M | 855.36M | 1.12B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 1.85B | 2.88B | 4.06B | 4.32B | 4B |
| Total Liabilities | 320.65M | 2.57B | 1.75B | 1.33B | 735.18M |
| Total Equity | 1.53B | 311.86M | 2.32B | 2.99B | 3.27B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 1.03B | 980.97M | 1.03B | 1.18B | 1.4B |
| Investing | -152.49M | -670.63M | -126.24M | -1.03B | 509.49M |
| Financing | -234.59M | -53.34M | 115.57M | -670.26M | -1.78B |
| Market Cap | 521.01M |
| Price to Earnings Ratio | 0.46 |
| Price to Sales Ratio | 0.17 |
| Price to Cash Ratio | 0.29 |
| Price to Book Ratio | 0.16 |
| Dividend Yield | - |
| Shares Outstanding | 627.65M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 24.5 (98%) |
| Company Name | SciClone Pharmaceutical Holdings Ltd (PK) |
| Address |
po box 309, ugland house grand cayman KY1-1104 |
| Website | https://www.sciclone.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
